Other substances

candidate vaccine

COVID-19 candidate vaccine

Phase of research

Potential treatment - theoretical effect

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
9
 Clinical trials

General information

The candidate vaccine being developed by GeoVax/BravoVax is an MVA encoded VLP type of candidate vaccine. It is based on the non-replicating viral vector platform, which is also used for non-COVID-19 candidates, such as LASV, EBOV, MARV, HIV. Currently, this COVID-19 candidate vaccine is in pre-clinical evaluation.

COVID-19 candidate vaccine on GeoVax

 

Supporting references

Link Tested on Impact factor Notes Publication date
DRAFT landscape of COVID-19 candidate vaccines – 26 March 2020
in vitro Mar/26/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04895449 Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19 Recruiting Phase 1 Jul/16/2021 Mar/01/2022
  • Alternative id - UKE-SARS-CoV-2-ST
  • Interventions - Biological: MVA-SARS-2-ST
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Uniklinik Köln, Cologne, NRW, Germany|CTC North, Hamburg, Germany
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 60
  • Age - 18 Years to 64 Years   (Adult)
  • Outcome measures - Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol|Number of participants who seroconverted
NCT04954131 Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China Active, not recruiting Phase 2 Aug/10/2021 Nov/15/2022
  • Alternative id - CLO-SCB-2019-010
  • Interventions - Biological: Candidate Vaccine, SCB-2019|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Shanxi Center for Disease Control and prevention, Taiyuan, Shanxi, China|Sichuan Center for disease control, Chengdu, Sichuan, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 766
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - GMT ratio of GMT-CLO-SCB-2019-010 over GMT-CLO-SCB-2019-003
NCT04569383 Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19 Completed Phase 1 Oct/05/2020 Aug/24/2021
  • Alternative id - UKE-DZIF-SARS-CoV-2
  • Interventions - Biological: MVA-SARS-2-S vaccinations (days 0 & 28)|Biological: Comirnaty
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CTC North GmbH & Co KG at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 30
  • Age - 18 Years to 55 Years   (Adult)
  • Outcome measures - Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol|Immunogenicity. Number of participants who seroconverted
NCT05228314 Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults Not yet recruiting Phase 1 Mar/01/2022 Sep/01/2023
  • Alternative id - CLO-SCB-2020S-002
  • Interventions - Biological: Candidate vaccine, SCB-2020S|Biological: Candidate vaccine, SCB-2019|Other: Squalene based adjuvant|Other: CpG/alum adjuvant
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 152
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Number of participants with local and systemic adverse events (AEs) after vaccination with SCB-2020S vaccine.|Number of participants with unsolicited AEs after vacccination with SCB-2020S vaccine|Number of participants with MAAEs, SAEs, AESIs and AEs leading to discontinuation from study.|Number of participants with abnormal results in hematology parameters (hemoglobin, platelet count, red blood cell count, total and differential white blood cell count).|Number of participants with abnormal results in biochemistry parameters (alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, total protein).|Number of participants with abnormal results in coagulation parameters (activated partial thromboplastin, prothrombin time).|Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibody (nAb)|Proportion of participants achieving seroconversion for SARS-CoV-2 nAb|Geometric Mean Fold Rise (GMFRs) of SARS-CoV-2 nAb|Proportion of participants with nAb above a certain threshold|GMT of SCB-2019 Binding Antibody|Proportion of participants achieving seroconversion for SCB-2019 binding antibody|GMFR of SCB-2019 binding antibody|SCB-2019 binding antibody above lower limit of quantification.
NCT05188677 Immunogenicity and Safety Study of a SCB-2019 Vaccine Booster Dose to Adults Who Previously Received Primary Series of Selected COVID-19 Vaccines Not yet recruiting Phase 3 Mar/01/2022 Feb/01/2023
  • Alternative id - CLO-SCB-2019-015
  • Interventions - Biological: Candidate vaccine, SCB-2019
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Clínica de la Costa Ltda, Barranquilla, Colombia|Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S., Cali, Colombia
  • Study designs - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 1000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Geometric Mean Titer (GMT) ratio of GMT booster over GMT primary series|SCR difference: Seroconversion Rate (SCR) booster minus SCR primary series;|Local and systemic solicited AEs reported within 7 days after study vaccination|Unsolicited AEs reported from Visit 1 (Day 1) through Safety Call Day 43|SAEs, AEs leading to early termination from the study, MAAEs, and AESIs|GMT ratio of GMT heterologous over GMT homologous;|SCR difference: SCR heterologous minus SCR homologous;
NCT05007509 Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19) Active, not recruiting Phase 1|Phase 2 Aug/16/2021 Sep/30/2022
  • Alternative id - HIPRA-HH-1|2021-001411-82
  • Interventions - Biological: COVID-19 vaccine HIPRA 10|Biological: COVID-19 vaccine HIPRA 20|Biological: COVID-19 vaccine HIPRA 40|Biological: Commercial COVID-19 vaccine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitari Dr. Josep Trueta, Girona, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 30
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number and percentage of solicited local and systemic reactogenicity adverse events for 7 days following each vaccination.|Number and percentage of unsolicited local and systemic reactogenicity adverse events for 28 days following each vaccination.|Change from baseline in hematology and biochemistry laboratory values at 7 days following each vaccination|Number and percentage of serious adverse events throughout the study duration.|Number and percentage of adverse events of special interest (AESI) throughout the study|Number and percentage of medically attended adverse events (MAAE) related to study vaccine throughout the study duration|Neutralization titer measured as Inhibitory concentration 50 (IC50) for each individual sample and geometric mean titer (GMT) for group comparison at Day 21 and 35|Geometric mean fold rise (GMFR) in neutralizing antibodies titers from baseline at Day 21 and 35.|Neutralization titer measured as IC50 for each individual sample and GMT for group comparison at 24 and 48 weeks after the second dose|GMFR in neutralizing antibodies titers from baseline at 24 and 48 weeks after the second dose.|Binding antibody IgG titer measured for each individual sample and GMT for group comparison at Day 21 and 35|GMFR in IgG titer from baseline at Day 21 and 35|Binding antibody IgG titer measured for each individual sample and GMT for group comparison at 24 and 48 weeks after the second dose.|GMFR in IgG titer from baseline at 24 and 48 weeks after the second dose|T-cell-mediated response to the SARS-CoV-2 S protein as measured by whole PBMC stimulation by ELISpot at baseline and at Day 35.|CD4+/CD8+ T-cell response to the SARS-CoV-2 S protein as measured by in vitro PBMC stimulation by cytokine staining assays at baseline and at Day 35
NCT05142553 Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against the Virus That Cause COVID-19, Know as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) in Healthy Adults Volunteers Fully Vaccinated Active, not recruiting Phase 2 Nov/16/2021 Dec/30/2022
  • Alternative id - HIPRA-HH-2
  • Interventions - Biological: COVID-19 Vaccine HIPRA|Biological: Cominarty (Pfizer-BioNtech)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Germans Trias I Pujol, Badalona, Barcelona, Spain|Hospital Principe de Asturias, Meco, Madrid, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital Vall Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari Dr. Josep Trueta, Girona, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Clínico de Valencia, Valencia, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 756
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Changes of the immunogenicity against Wuham|Safety and tolerability of PHH-1V|Changes of the immunogenicity against the Variants of Concern (VOC)|Changes in immunogenicity at Baseline and Days 14, 28, 182 &364.|Immunogenicity to the SARS-CoV-2 spike glycoprotein at Baseline and Days 14, 28, 182&364|T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline & D14.|Th-1/Th-2 T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline & D14. Th-1/Th2
NCT05193279 Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age Not yet recruiting Phase 2|Phase 3 Mar/01/2022 Jul/01/2024
  • Alternative id - CLO-SCB-2019-007
  • Interventions - Biological: Candidate vaccine, SCB-2019
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Clínica de la Costa Ltda, Barranquilla, Colombia|Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S., Cali, Colombia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 3820
  • Age - up to 17 Years   (Child)
  • Outcome measures - Phase 2, select optimal dose level of SCB-2019 vaccine by age cohort (5-11 years, 2-4 years, and < 2 years), based on safety|Phase 2, select optimal dose level of SCB-2019 vaccine in phase 2 by age cohort (5-11 years, 2-4 years, and < 2 years), based on immunogenicity|Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 5 to < 12 years as compared to young adults (18 to < 25 years)|Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 2 to < 5 years as compared to young adults (18 to < 25 years)|Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants birth to < 2 years as compared to young adults (18 to < 25 years)|Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 5 to < 12 years as compared to young adults (18 to < 25 years)|Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 2 to < 5 years as compared to young adults (18 to < 25 years)|Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants birth to < 2 years as compared to young adults (18 to < 25 years)|In phase 2 and 3, GMT of SARS-CoV-2 nAb|In phase 2 and 3, proportion of participants achieving seroconversion for SARS-CoV-2 nAb|In phase 2 and 3, GMFR in SARS-CoV-2 nAb|In phase 2 and 3, proportion of participants with SARS-CoV-2 nAb above a certain threshold|In phase 2 and 3, GMT of SCB-2019 Binding Antibody|In phase 2 and 3, proportion of participants achieving seroconversion for SCB-2019 binding antibody|In phase 2 and 3, GMFR of SCB-2019 binding antibody|In phase 2 and 3, proportion of participants with SCB-2019 binding antibody above a certain threshold|In phase 3, reactogenicity of the vaccine as indicated by the occurrence of solicited local and systemic reactions|Phase 2 and 3, safety of the vaccine in terms of occurrence of unsolicited adverse events|Phase 2 and 3, safety of the vaccine in terms of occurrence of MAAEs, SAEs, adverse events leading to discontinuation from study, and AESIs.
NCT04950751 Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults Withdrawn Phase 2 Aug/01/2021 Apr/01/2022
  • Alternative id - CLO-SCB-2020-001
  • Interventions - Biological: candidate vaccine, SCB-2020S
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibodies to B.1.351 variant|Proportion of subjects achieving seroconversion of SARS-CoV-2 neutralising antibodies to B.1.351 variant|Geometric mean fold rise (GMFR) of SARS-Cov-2 neutralising antibodies to B.1.351 variant|Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibodies to Wuhan strain|Proportion of subjects achieving seroconversion of SARS-CoV-2 neutralising antibodies to Wuhan strain|Geometric mean fold rise (GMFR) of SARS-Cov-2 neutralising antibodies to Wuhan strain|Geometric mean titer (GMT) of antibody titers specific to SCB-2019 antigen|Proportion of subjects achieving seroconversion of antibodies specific to SCB-2019|Geometric mean fold rise (GMFR) of antibodies specific to SCB-2019|Reactogenicity of the vaccines as indicated by the occurrence of solicited local reactions and solicited systemic adverse events.|Safety of the vaccines in terms of the occurrence of unsolicited adverse events|Safety of the vaccines in terms of the occurrence of medically attended adverse events (MAAEs), serious adverse events (SAEs), adverse events leading to discontinuation from study, and adverse events of special interest (AESI).|Proportion of subjects with abnormal markers of hematology, biochemistry and coagulation parameters
Export (.csv)